Rapport Therapeutics, Inc. (NASDAQ:RAPP) Receives Average Recommendation of “Moderate Buy” from Brokerages

Rapport Therapeutics, Inc. (NASDAQ:RAPP) has earned an average rating of “Moderate Buy” from the nine brokerages that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, seven have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $51.40.

RAPP has been the subject of a number of recent research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Rapport Therapeutics in a report on Thursday, January 22nd. TD Cowen restated a “buy” rating on shares of Rapport Therapeutics in a report on Monday, March 9th. Wall Street Zen downgraded shares of Rapport Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 14th. BTIG Research boosted their price objective on shares of Rapport Therapeutics to $47.00 and gave the stock a “buy” rating in a research note on Monday, March 9th. Finally, HC Wainwright increased their target price on shares of Rapport Therapeutics from $34.00 to $40.00 and gave the company a “buy” rating in a research report on Tuesday, December 9th.

Insider Transactions at Rapport Therapeutics

In other news, COO Cheryl Gault sold 2,014 shares of the stock in a transaction on Thursday, March 5th. The stock was sold at an average price of $28.93, for a total transaction of $58,265.02. Following the completion of the sale, the chief operating officer owned 169,914 shares in the company, valued at approximately $4,915,612.02. This represents a 1.17% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Abraham Ceesay sold 5,833 shares of the firm’s stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $26.12, for a total value of $152,357.96. Following the completion of the sale, the chief executive officer directly owned 562,080 shares of the company’s stock, valued at $14,681,529.60. The trade was a 1.03% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 40,846 shares of company stock valued at $1,138,527. Corporate insiders own 13.57% of the company’s stock.

Institutional Investors Weigh In On Rapport Therapeutics

A number of large investors have recently modified their holdings of RAPP. Baker BROS. Advisors LP grew its stake in shares of Rapport Therapeutics by 181.2% during the third quarter. Baker BROS. Advisors LP now owns 1,547,090 shares of the company’s stock worth $45,949,000 after acquiring an additional 997,000 shares during the last quarter. Vestal Point Capital LP purchased a new position in shares of Rapport Therapeutics in the 3rd quarter valued at approximately $28,215,000. Polar Capital Holdings Plc acquired a new stake in Rapport Therapeutics in the 3rd quarter worth approximately $27,887,000. Capital International Investors boosted its stake in Rapport Therapeutics by 30.7% in the 3rd quarter. Capital International Investors now owns 3,402,529 shares of the company’s stock worth $101,055,000 after purchasing an additional 800,000 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in Rapport Therapeutics by 265.9% during the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 892,258 shares of the company’s stock worth $26,500,000 after purchasing an additional 648,378 shares during the last quarter.

Rapport Therapeutics Stock Performance

Shares of NASDAQ:RAPP opened at $33.58 on Friday. The company has a market capitalization of $1.61 billion, a PE ratio of -11.74 and a beta of 1.09. Rapport Therapeutics has a 12-month low of $7.73 and a 12-month high of $42.27. The business’s fifty day simple moving average is $28.59 and its 200-day simple moving average is $27.95.

Rapport Therapeutics (NASDAQ:RAPP) last issued its quarterly earnings data on Tuesday, March 10th. The company reported ($0.72) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.07). Research analysts predict that Rapport Therapeutics will post -3.65 EPS for the current year.

About Rapport Therapeutics

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for patients with cancer. The company leverages a proprietary discovery engine to identify novel tumor-associated antigens and develop tailored biologic and small-molecule candidates designed to modulate key oncogenic pathways. With a pipeline comprising multiple preclinical and early clinical assets, Rapport is committed to advancing precision medicine approaches and addressing unmet needs in oncology.

Rapport’s discovery engine combines high-throughput screening, molecular profiling and in vivo validation to accelerate the progression of lead candidates from the laboratory to clinical evaluation.